T1	Process 20 39	pharmacyte approach
T2	Material 84 95	ACT T-cells
T3	Material 136 149	adjuvant drug
T4	Process 189 200	stimulation
T5	Process 226 266	expansion of the cell population in vivo
T6	Material 274 294	cell-bound particles
T7	Process 317 330	cell division
T8	Material 317 321	cell
T9	Material 374 390	supporting drugs
T10	Material 394 401	T-cells
T11	Material 407 433	nanoparticle drug carriers
T12	Material 464 487	transferred lymphocytes
T13	Material 521 546	supporting adjuvant drugs
T14	Task 655 689	elimination of large tumor burdens
T15	Process 696 740	“re-arming” of T-cells with supporting drugs
T16	Material 711 718	T-cells
T17	Material 724 740	supporting drugs
T18	Material 789 807	targeted particles
T19	Process 771 807	administration of targeted particles
T20	Material 818 848	adoptively-transferred T-cells
T21	Material 918 949	internalizing targeting ligands
T22	Material 1012 1032	nanoparticle carrier
T23	Material 1100 1113	nanoparticles
T24	Material 1117 1124	T-cells
T25	Material 1195 1202	T-cells
T26	Material 1207 1226	peptide-MHC ligands
T27	Material 1249 1265	T-cell receptors
T28	Material 1276 1316	peptide-MHC-functionalized nanoparticles
T29	Material 1388 1395	T-cells
T30	Task 1425 1465	treating graft rejection or autoimmunity
T31	Task 1500 1520	cancer immunotherapy
